{"id":"W2099988058","doi":"10.1186/1471-2407-11-313","title":"Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study","year":2011,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer; Amgen; American Heart Association","keywords":"Erlotinib; Gemcitabine; Medicine; Pharmacokinetics; Pharmacology; Nausea; Adverse effect; Internal medicine; Phases of clinical research; Oncology; Tolerability; Epidermal growth factor receptor; Gastroenterology; Toxicity; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002282703,0.00009967397,0.0002958427,0.00007447744,0.00002451566,0.000002713181,0.00004453889,0.00002081074,0.00006742563],"category_scores_gemma":[0.00002851797,0.00006037432,0.00002043,0.0001483411,0.0001367672,0.00002590575,0.00001519283,0.00005045352,1.12786e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009421669,"about_ca_system_score_gemma":0.0001628617,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001384292,"about_ca_topic_score_gemma":0.001459144,"domain_scores_codex":[0.9992083,0.00003715999,0.0002509259,0.0001677175,0.0001910127,0.0001448232],"domain_scores_gemma":[0.9994012,0.0001521187,0.00009055727,0.0001629931,0.0001383951,0.00005478568],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03155772,0.01898126,0.7192971,0.001332657,0.0005603344,0.0000238282,0.03415921,0.00005534953,0.007586818,0.0001451092,0.0002141748,0.1860865],"study_design_scores_gemma":[0.1571675,0.04253953,0.7191453,0.0005957762,0.0007846899,0.00001956677,0.004708065,0.01090452,0.06084026,0.00007768065,0.002961576,0.0002555305],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944413,0.001978725,0.0003408774,0.0001397921,0.00003063764,0.002874264,0.00009147458,0.00000603226,0.0000969559],"genre_scores_gemma":[0.9977022,0.001266812,0.000453619,0.00001794168,0.00003885892,0.0003466667,0.000003460438,0.00001771923,0.0001526729],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.185831,"threshold_uncertainty_score":0.2461993,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1121455682981794,"score_gpt":0.4283166535785267,"score_spread":0.3161710852803472,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}